Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes

Transplantation
T B PrigozhinaS Slavin

Abstract

The long-term success of organ transplantation is limited by complications resulting from consistent nonspecific immunosuppression. Induction of stable, donor-specific tolerance remains the main goal of transplantation immunology. In this article, a new, nonmyeloablative method is described for induction of transplantation tolerance to fully mismatched bone marrow cells (BMC), bone marrow stromal precursors, heart muscle, and skin allografts. The method is based on pretransplant conditioning with no postgraft immunosuppression, and consists of a short course (six daily fractions of 200 cGy) of total lymphoid irradiation (sTLI), followed by selective elimination of donor-specific alloreactive cells of the host escaping low-dose sTLI. Donor-specific alloreactive cells were activated by intravenous inoculation with a high dose of donor BMC (3 x 10(7) cells) 1 day after sTLI, and eliminated by a single intraperitoneal dose (200 mg/kg) of cyclophosphamide given 1 day after cell transfer. Infusion of a low number of T cell-depleted BMC (3 x 10(6) cells) after tolerogenic preconditioning converted recipients to stable mixed chimeras free of graft-versus-host disease. The same treatment provided long-lasting acceptance of heterotopical...Continue Reading

References

Feb 1, 1985·European Journal of Immunology·S MoreckiS Slavin
Jun 1, 1987·The Journal of Experimental Medicine·S MoreckiS Slavin
Jul 1, 1988·Biulleten' eksperimental'noĭ biologii i meditsiny·I Iu CherniakhovskaiaL N Fontalin
Sep 1, 1984·Transplantation· Chernyakhovskaya IYuL N Fontalin
Jan 1, 1981·International Journal of Radiation Oncology, Biology, Physics·Z Fuks, S Slavin
Dec 1, 1993·The Annals of Thoracic Surgery·D H Sachs
Jan 1, 1987·Immunology Today·S Slavin

❮ Previous
Next ❯

Citations

Sep 28, 2000·Current Opinion in Immunology·S Slavin
Jul 29, 2003·Transplantation·Shimon Slavin
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·H MoritaS Ikehara
Feb 17, 2007·Critical Reviews in Oncology/hematology·Michael Y ShapiraS Slavin
Jan 24, 2004·Pediatric Transplantation·Eric G JacquetSuzanne T Ildstad
Jul 21, 2004·Journal of the Neurological Sciences·Dimitrios Karussis, Shimon Slavin
Apr 28, 2005·Transplant International : Official Journal of the European Society for Organ Transplantation·Toshiro IwaiHisataka Yasui
Dec 10, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Margot Zöller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.